Skin Substitutes Market Size, Share, Industry, Forecast and outlook (2023-2030)

Global Skin Substitutes Market is segmented By Type (Synthetic Skin Substitute, Biosynthetic Skin Substitute, Biological Skin Substitute (Allograft (Cellular, Acellular), Xenograft, Amnion)), By Application (Burn Injuries, Diabetic Foot Ulcers, Chronic Wounds, Others), By End User (Hospitals, Other Healthcare Facilities), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Skin Substitutes Market Overview

[180 Pages] Report on Skin Substitutes Market size was valued US$ 946.4 million in 2021 and is estimated to reach US$ 2,078.3 million by 2030, growing at a CAGR of 15.5% during the forecast period 2023-2030.

Skin substitutes are natural, synthetic or biosynthetic materials used to cover large wounds to restore at least some of the functions of the skin. Skin substitutes provide temporary or permanent wound closure and protect the wound from infection, further damage and water loss, and reduce pain. They also facilitate the growth of the normal skin over the wound.

Skin substitutes provide a permanent solution and are used to treat conditions like burns, trauma wounds, diabetes or venous ulcers, where skin grafts may not be possible.

Skin Substitutes Market Scope and Summary

Skin Substitutes Market Trends and Dynamics

The major driving forces are the rising incidence of burn injuries, new approached in tissue engineered skin substitutes and growing geriatric population will all drive the growth of skin substitutes market.

Increasing chronic skin disease and rising awareness are expected to drive the market growth.

Rising chronic skin diseases are expected to drive the global skin substitutes market. For instance, according to the global burden of disease study, skin conditions contributed around 1.79% to the global disease burden. According to the World Health Organization, about 132,000 melanoma skin cancers occur each year worldwide. Thus, the rising chronic diseases are increasing the demand for skin substitutes in the forecast period.

The rising prevalence of diabetes is expected to boost the market. This is due to the risk of developing a diabetic foot ulcer over time in diabetic patients. For instance, WHO has reported that the incidence of diabetes for all age groups worldwide was estimated to be 2.8% in 2000 and 4.4% in 2030. The total number of people with diabetes is anticipated to rise from 171 million in 2000 to 366 million in 2030. Thus, as a consequence, the prevalence of diabetes-related complications is expected to increase over the forecast period.

Rising awareness between people about treatment options available in the market are also going to drive the market growth in forecast period. People are looking for advanced and novel burn care products and launching new products will fuel the market growth. Availability of range of products in market will increase the market.

Lack of inability of reproducing skin appendages and capability of replacing lost dermis are expected to hamper the market growth.

There are several limitations to the commercially available skin substitutes, like reduced vascularization, poor mechanical integrity, failure to integrate, scarring, and immune rejection. Also, the currently available skin substitutes mainly consist of fibroblasts and keratinocytes. Hence, they lack the ability to make differentiated structures, like hair and sweat glands. Therefore, there is a need to include additional cell types, such as endothelial cells, in engineered skin.

Industry Analysis

The global skin substitutes market provides in-depth analysis of the market based on various industry factors such as porter’s five forces, regulatory analysis, supply chain analysis, pricing analysis, product innovations and unmet needs.

Skin Substitutes Market Segmentation Analysis

Acellular skin substitutes segment is expected to hold the largest market share in global skin substitutes market

The rise in preference for acellular skin substitutes to implant-based skin surgery is expected to drive the growth of the global skin substitutes market. For instance, the American Society of Plastic Surgeons in 2020 reported that more than 60% of surgeons in the US had preferred acellular matrix for skin surgeries. The rising incidence rate of skin disorders across the globe may lead to an increased number of patients who will undergo either invasive or non-invasive skin surgeries. For instance, according to the American Academy of Dermatology, one in five persons in the US is expected to develop skin disorders in their lifetime.

Several acellular skin substitutes in the market are expected to drive the global skin substitutes market. For instance, Alloderm of LifeCell Inc., Branchburg, NJ, USA, OASIS Wound Matrix of Cook Biotech Inc., West Lafayette, IN, USA, and Integra DRT (dermal regeneration template) Integra LifeSciences Corp., USA are some of the acellular skin substitutes prevailing in the market.

The burn injuries market is largest share-holder and is estimated to grow at a highest CAGR over the forecast period. Rising incidences of burn injuries are expected to drive the market. For instance, according to the World health organization, an estimated 180 000 deaths, every year are caused by burns – the vast majority occur in low- and middle-income countries. Also, the presence of novel approaches in the treatment of burns is expected to drive the market. For instance, 3D bioprinting, transformative technology for the reconstruction of burn wounds, enables accurate placement of cell types and allows precise and reproducible fabrication of constructs that replaces the injured or damaged sites. Thus, its use for wound reconstruction will lead to a paradigm shift in patient outcomes.

Global Skin Substitutes Market Geographical Share

North America region holds the largest market share in the global skin substitutes market

The skin substitutes market is expected to grow at a high CAGR during the forecasting period. The U.S. holds a high percentage of the market share and North America holds the major market share for skin substitutes due to increasing burns and chronic skin diseases. Rising cases of burns are expected to drive the market over the period of forecast. For instance, according to the global burden of disease report 2020, total 8.378,122 new burn cases were found globally. And around 111,292 deaths were accounted in 2019. According to the American burn association, in 2019, over 60% of the estimated US acute hospitalizations related to burns were admitted to 128 burn centers. Also, the healthcare burden, which includes direct costs for care of children with burns in the United States of America, exceeded US$ 211 million. The presence of key players, Mergers between the major companies in the healthcare devices for research and development in skin substitutes, FDA approvals, and new product launches are expected to drive the global skin substitutes market. For instance, key players like LifeCell Inc, Cook Biotech Inc, and Mylan Bertek Pharmaceuticals are some of the major key players in the region. In Jan 2021, Integra Lifesciences announced it acquisition of ACell a regenerative medicine firm. This will expand integra’s tissue and orthopedics segment by including various innovative products of ACell.

Skin Substitutes Companies and Competitive Landscape

The skin substitutes market is highly competitive with the presence of a large number of players including Amarantus BioScience Holding, Organogenesis, Inc., Acelity L.P., Inc., Smith & Nephew plc, BSN Medical, Molnlycke Health Care, Integra LifeSciences Corporation, Medtronic, Tissue Regenix Ltd., Stratatech Corporation and ConVatec.

The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations which are contributing to the growth of the skin substitutes market globally. For instance,

• In Aug 2022, Organogenesis, regenerative medicine company announced clearance of PuraPly MZ by U.S. Food and Drug Administration. This product enhances the innovative functions of PuraPly technology as it is engineered into powdered or micronized form that will ease complex surgical wound treatment
• In Jan 2021, Organogenesis, regenerative medicine company that develops and markets product solutions for advanced surgical & sports medicine and wound care announced its product ReNu was granted as regenerative medicine advanced therapy designation by U.S. Food and Drug Administration. ReNu is cryopreserved amniotic suspension allograft for symptoms with knee osteoarthritis.   
• In Sep 2021, Tissue Regenix, regenerative medicine technology launched DermaPure Meshed and VNEW, both the products come under Biosurgery division and are using decellularization technology of Tissue Regenix.

Amarantus BioScience Holdings:

Overview: Amarantus Bioscience is a biotech company that develops therapeutic products in neurology, regenerative medicine, ophthalmology and psychiatry fields that are potent for orphan drug designation. It was founded in 2008 and is headquartered in San Francisco, United States.

Product Portfolio:

Engineered Skin Substitutes: It is tissue engineered skin that is developed from skin cells of patient. Cultured epithelium and collagen fibroblast implant are combined that develops skin substitute with dermal and epidermal, both components.

Key Developments: In Jan 2020, Amarantus Bioscience announced its acquisition of controlling interest in Hempori Inc., CBD Wellness in Dallas.

The global skin substitutes market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.